Cognitive therapy (CT) combined with taking an antidepressant leads to better outcomes than taking an antidepressant alone, though the effect appears limited only to patients suffering from severe depression that is not chronic.
Steven D. Hollon, PhD, of the Department of Psychology at Vanderbilt University, Nashville, Tennessee, and colleagues examined 452 adult outpatients with chronic or recurrent major depressive disorder (MDD), who were randomly assigned to antidepressant treatment only or CT combined with an antidepressant. Treatment was administered for up to 42 weeks until recovery.
Combined treatment enhanced the rate of recovery vs. treatment with an antidepressant alone (72.6% vs 62.5%; t451= 2.45; P=0.01; hazard ratio, 1.33; 95% C: 1.06-1.68; number needed to treat, 10; 95% CI: 5-72), the researchers reported in JAMA Psychiatry.
However, those results were conditioned on severity and chronicity of the depression, such that the advantage for combined treatment was limited to patients with severe, nonchronic MDD (81.3% vs. 51.7%; n=146; t145=3.96; P=0.001; HR, 2.34; 95% CI, 1.54-3.57; NNT, 3; 95% CI, 2-5).
Patients with comorbid Axis II disorders took longer to recover than did patients without comorbid Axis II disorders regardless of the condition (P=0.01). Also, patients who received combined treatment reported fewer serious adverse events than did patients who received antidepressants alone (49 vs. 71; P=0.02), largely because they experienced less time in an MDD episode.
Antidepressant medication (ADM) is efficacious in the treatment of depression, but not all patients achieve remission and fewer still achieve recovery with ADM alone. The objective of the study is to determine the effects of combining cognitive therapy with ADM vs ADM alone on remission and recovery in major depressive disorder.
READ FULL ARTICLE
From http://archpsyc.jamanetwork.com/article.aspx?articleid=1897300&utm_campaign=social_081314&utm_medium=twitter&[email protected]
Enjoying our content?
Thanks for visiting Psychiatry Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Psychiatry Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Evidence-Based Guidance
- Conference Coverage
- Unique Psychiatry Case Studies
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.